BRKR Quote, Financials, Valuation and Earnings

Avantor has a net margin of 1.4% compared to Bruker's net margin of 4.08%. Bruker's return on equity of 6.78% beat Avantor's return on equity of 12.61%.

Bruker has a consensus price target of $58.59, signalling upside risk potential of 43.75%. On the other hand Avantor has an analysts' consensus of $16.98 which suggests that it could grow by 42.25%. Given that Bruker has higher upside potential than Avantor, analysts believe Bruker is more attractive than Avantor.

Bruker has a beta of 1.228, which suggesting that the stock is 22.782% more volatile than S&P 500. In comparison Avantor has a beta of 1.088, suggesting its more volatile than the S&P 500 by 8.795%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.49%. Avantor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 26.7% of its earnings as a dividend. Avantor pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $979.6M, which are smaller than Avantor quarterly revenues of $1.6B. Bruker's net income of $13.7M is lower than Avantor's net income of $64.5M. Notably, Bruker's price-to-earnings ratio is 53.63x while Avantor's PE ratio is 11.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.81x versus 1.22x for Avantor. Usually stocks with elevated PS ratios are considered overvalued.

Azenta has a net margin of 1.4% compared to Bruker's net margin of -9.04%. Bruker's return on equity of 6.78% beat Azenta's return on equity of -7.97%.

Bruker has a consensus price target of $58.59, signalling upside risk potential of 43.75%. On the other hand Azenta has an analysts' consensus of $41.00 which suggests that it could grow by 62.31%. Given that Azenta has higher upside potential than Bruker, analysts believe Azenta is more attractive than Bruker.

Bruker has a beta of 1.228, which suggesting that the stock is 22.782% more volatile than S&P 500. In comparison Azenta has a beta of 1.638, suggesting its more volatile than the S&P 500 by 63.767%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.49%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 26.7% of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $979.6M, which are larger than Azenta quarterly revenues of $147.5M. Bruker's net income of $13.7M is higher than Azenta's net income of -$13.3M. Notably, Bruker's price-to-earnings ratio is 53.63x while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.81x versus 1.96x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Rad Laboratories has a net margin of 1.4% compared to Bruker's net margin of 10.93%. Bruker's return on equity of 6.78% beat Bio-Rad Laboratories's return on equity of -29.59%.

Bruker has a consensus price target of $58.59, signalling upside risk potential of 43.75%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $318.67 which suggests that it could grow by 37.03%. Given that Bruker has higher upside potential than Bio-Rad Laboratories, analysts believe Bruker is more attractive than Bio-Rad Laboratories.

Bruker has a beta of 1.228, which suggesting that the stock is 22.782% more volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 0.999, suggesting its less volatile than the S&P 500 by 0.087999999999999%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.49%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 26.7% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $979.6M, which are larger than Bio-Rad Laboratories quarterly revenues of $585.4M. Bruker's net income of $13.7M is lower than Bio-Rad Laboratories's net income of $64M. Notably, Bruker's price-to-earnings ratio is 53.63x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.81x versus 2.57x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of 1.4% compared to Bruker's net margin of 0.07%. Bruker's return on equity of 6.78% beat Harvard Bioscience's return on equity of -18.36%.

Bruker has a consensus price target of $58.59, signalling upside risk potential of 43.75%. On the other hand Harvard Bioscience has an analysts' consensus of $4.50 which suggests that it could grow by 1400%. Given that Harvard Bioscience has higher upside potential than Bruker, analysts believe Harvard Bioscience is more attractive than Bruker.

Bruker has a beta of 1.228, which suggesting that the stock is 22.782% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.441, suggesting its more volatile than the S&P 500 by 44.128%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.49%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 26.7% of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $979.6M, which are larger than Harvard Bioscience quarterly revenues of $24.6M. Bruker's net income of $13.7M is higher than Harvard Bioscience's net income of $18K. Notably, Bruker's price-to-earnings ratio is 53.63x while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.81x versus 0.14x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.